Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Hypocellular acute leukemia]

M Tomonaga1

  • 1Department of Hematology, Atomic Disease Institute Nagasaki University School of Medicine, Nagasaki.

[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology
|May 1, 1995
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A new G-CSF-supported combination chemotherapy, LSG15, for adult T-cell leukaemia-lymphoma: Japan Clinical Oncology Group Study 9303.

British journal of haematology·2001
Same author

Morphological diagnoses of the Japan adult leukemia study group acute myeloid leukemia protocols: central review.

International journal of hematology·2001
Same author

Effect of a selective Abl tyrosine kinase inhibitor, STI571, on in vitro growth of BCR-ABL-positive acute lymphoblastic leukemia cells.

Leukemia·2001
Same author

Cytogenetic analysis and clinical significance in adult T-cell leukemia/lymphoma: a study of 50 cases from the human T-cell leukemia virus type-1 endemic area, Nagasaki.

Blood·2001
Same author

Tumor necrosis factor alpha polymorphism associated with increased susceptibility to development of adult T-cell leukemia/lymphoma in human T-lymphotropic virus type 1 carriers.

Cancer research·2001
Same author

Expression of survivin in HTLV-I-infected T-cell lines and primary ATL cells.

Biochemical and biophysical research communications·2001

Hypocellular acute leukemia (HL) is a distinct elderly AML subtype defined by low bone marrow cellularity (<40%) and significant blasts (≥30%). This condition presents unique diagnostic challenges and treatment responses.

Area of Science:

  • Hematology
  • Oncology
  • Bone Marrow Pathology

Context:

  • Distinguishing hypocellular acute leukemia (HL) from myelodysplastic syndromes (MDS) and other acute myeloid leukemia (AML) subtypes is clinically significant.
  • Elderly patients (≥60 years) with low bone marrow cellularity present diagnostic challenges.
  • Previous diagnostic criteria for HL were not clearly established.

Purpose:

  • To establish clear diagnostic criteria for hypocellular acute leukemia (HL).
  • To differentiate HL from MDS and AML in both elderly and young populations.
  • To analyze the characteristics and treatment outcomes of HL.

Summary:

  • This study analyzed 32 cases of HL (≤40% bone marrow cellularity) and compared them with 40 MDS and 66 AML cases.

Related Experiment Videos

  • HL cases exhibited significantly lower mean bone marrow cellularity (30%) compared to MDS (85%) and AML (87-95%).
  • HL demonstrated maturation arrest of blast cells, consistent with overt AML, with blast percentages ranging from 17-70% (ANC) and 36-93% (NLC).
  • Treatment with low-dose cytarabine (ara-C) in 20 HL cases resulted in a 65% complete remission rate, though most relapsed with hypocellular marrow.

    • Impact:

    • Hypocellular acute leukemia (HL) is identified as a distinct clinical subtype of AML in the elderly.
    • Diagnostic criteria for HL are proposed: ≤40% bone marrow cellularity and ≥30% blasts.
    • Understanding HL as a unique entity may guide future therapeutic strategies and improve patient outcomes.